Atopic Dermatitis (AD) affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of its triggers and includes emollients, topical steroids and calcineurin inhibitors among others. Immunological dysfunction can be addressed broadly with systemic immunosupressors and specifically with monoclonal antibodies. Dupilumab, which targets IL-4 and IL-13 was granted approval for treatment of moderate-to-severe AD. Biologics targeting IgE/Th2 pathways may have its role in patients with overlapping AD and asthma. Psychological distress can exacerbate symptoms and is associated with increased severity of AD. Environmental triggers, such as, allergens can be addressed in selected cases with allergic immunotherapy. In this paper, we discuss AD treatment and propose a new step-by-step approach aiming at maintaining disease control and improving quality of life.
moderate disease, suggesting caution in their use in more advanced stages of the disease 151 and in infants. (15) . The incidence of reported side effects from TCS use is low; however, 152 most studies fail to follow patients long-term for potential complications. Cutaneous 153 side effects include purpura, telangiectasias, striae, focal hypertrichosis, and acneiform 154 or rosacea-like eruptions. Of greatest concern is skin atrophy, which can be induced by 
